Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Nefita** is a Steadfast renal-nutrition multivitamin brand intended to replenish water-soluble vitamins in people with kidney disease, including patients undergoing dialysis. The tablet formulation contains ascorbic acid, niacinamide, pyridoxine, folic acid, pantothenic acid, riboflavin, thiamine, methylcobalamin, and biotin; it is marketed for vitamin replacement where intake is inadequate or vitamin losses are excessive, including chronic renal failure and uremia. Steadfast also markets a Nefita injection with a different fixed combination of methylcobalamin, folic acid, niacinamide, and pyridoxine for post-dialysis nutritional support and anemia-related use. The Nefita name therefore covers more than one dosage form and composition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nefita.